Reviva Pharmaceuticals Holdings Book Value Per Share Growth & History (RVPH)
Reviva Pharmaceuticals Holdings's book value per share was $1.47 for fiscal 2025.
View full Reviva Pharmaceuticals Holdings company overviewReviva Pharmaceuticals Holdings annual book value per share history
| Fiscal year | Period ended | Book value per share | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $1.47 | $1.13 | +327.54% |
| 2024 | 2024-12-31 | $0.34 | $0.14 | +68.14% |
| 2023 | 2023-12-31 | $0.20 | -$0.21 | −50.10% |
| 2022 | 2022-12-31 | $0.41 | -$1.58 | −79.34% |
| 2021 | 2021-12-31 | $1.99 | $1.40 | +235.70% |
| 2020 · Dec 31 | 2020-12-31 | $0.59 | $3.05 | — |
| 2020 · Feb 29 | 2020-02-29 | $1.85 | -$0.07 | −3.78% |
| 2019 · Dec 31 | 2019-12-31 | -$2.46 | — | — |
| 2019 · Feb 28 | 2019-02-28 | $1.92 | — | — |
Reviva Pharmaceuticals Holdings quarterly book value per share
| Fiscal quarter | Period ended | Book value per share | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $1.16 | $1.17 | — |
| Q1 2026 | 2026-03-31 | $1.36 | $1.46 | — |
| Q4 2025 | 2025-12-31 | $1.47 | $1.13 | +327.54% |
| Q3 2025 | 2025-09-30 | $0.05 | $0.35 | — |
| Q2 2025 | 2025-06-30 | -$0.01 | $0.20 | — |
| Q1 2025 | 2025-03-31 | -$0.10 | -$0.05 | — |
| Q4 2024 | 2024-12-31 | $0.34 | $0.14 | +68.14% |
| Q3 2024 | 2024-09-30 | -$0.30 | $0.32 | — |
| Q2 2024 | 2024-06-30 | -$0.20 | -$0.12 | — |
| Q1 2024 | 2024-03-31 | -$0.05 | -$0.13 | — |
| Q4 2023 | 2023-12-31 | $0.20 | -$0.21 | −50.10% |
| Q3 2023 | 2023-09-30 | -$0.62 | -$1.62 | — |
| Q2 2023 | 2023-06-30 | -$0.08 | -$1.19 | — |
| Q1 2023 | 2023-03-31 | $0.08 | -$1.33 | −94.41% |
| Q4 2022 | 2022-12-31 | $0.41 | -$1.58 | −79.34% |
| Q3 2022 | 2022-09-30 | $1.00 | -$1.41 | −58.68% |
| Q2 2022 | 2022-06-30 | $1.11 | -$1.47 | −56.84% |
| Q1 2022 | 2022-03-31 | $1.41 | $0.92 | +188.52% |
| Q4 2021 | 2021-12-31 | $1.99 | $1.40 | +235.70% |
| Q3 2021 · Sep 30 | 2021-09-30 | $2.41 | — | — |
| Q2 2021 · Jun 30 | 2021-06-30 | $2.58 | — | — |
| Q1 2021 · Mar 31 | 2021-03-31 | $0.49 | — | — |
| Q4 2020 · Dec 31 | 2020-12-31 | $0.59 | $1.33 | — |
| Q3 2021 · Nov 30 | 2020-11-30 | $1.75 | -$0.16 | −8.26% |
| Q2 2021 · Aug 31 | 2020-08-31 | $1.78 | -$0.13 | −6.97% |
| Q1 2021 · May 31 | 2020-05-31 | $1.82 | -$0.10 | −5.02% |
| Q4 2020 · Feb 29 | 2020-02-29 | $1.85 | -$0.07 | −3.78% |
| Q4 2019 · Dec 31 | 2019-12-31 | -$0.74 | — | — |
| Q3 2020 | 2019-11-30 | $1.91 | -$0.02 | −0.87% |
| Q2 2020 | 2019-08-31 | $1.92 | -$0.01 | −0.54% |
| Q1 2020 | 2019-05-31 | $1.92 | — | — |
| Q4 2019 · Feb 28 | 2019-02-28 | $1.92 | — | — |
| Q3 2019 | 2018-11-30 | $1.92 | — | — |
| Q2 2019 | 2018-08-31 | $1.93 | — | — |
Reviva Pharmaceuticals Holdings book value per share trends
Over the last five fiscal years, Reviva Pharmaceuticals Holdings's book value per share increased from $0.59 to $1.47, a change of $0.88. The latest reported quarter, Q2 2026, shows $1.16.
What book value per share means
Book value per share estimates the common shareholders’ accounting equity represented by each share. It can help compare a company’s balance-sheet value over time, although market value can differ substantially from book value.
How book value per share is calculated
TickerStat calculates book value per share as SEC-reported common shareholders’ equity divided by reported period-end common shares. Preferred equity is subtracted when separately reported, and basic weighted-average shares are used only when period-end shares are unavailable. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Reviva Pharmaceuticals Holdings source filings ↗